Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis

Area of Science:

• Neuroimmunology
• Molecular Biology
• Genetics

Background:

• Benign multiple sclerosis (BMS) affects approximately 15% of relapsing-remitting multiple sclerosis (RRMS) patients, characterized by minimal neurological disability progression.
• The underlying molecular mechanisms differentiating BMS from typical RRMS remain poorly understood.

Purpose of the Study:

• To elucidate the biological mechanisms and gene expression signatures associated with benign multiple sclerosis (BMS).
• To identify key molecular pathways contributing to the low disease activity observed in BMS patients.

Main Methods:

• Gene expression microarray analysis (HG-U133A-2 array) was performed on blood samples from 31 BMS patients and 36 RRMS patients.
• Data analysis involved Partek software, with pathway reconstruction for informative genes conducted using Ingenuity.
• Quantitative reverse transcription PCR (qRT-PCR) was used to validate key gene expression findings.

Main Results:

• A distinct gene expression signature of 406 informative genes was identified between BMS and RRMS patients.
• The most significant under-expressed pathway in BMS was RNA polymerase I (POL-1) transcription (p = 4.0*10(-5)), which is known to suppress NFκB-induced inflammation and activate P53-dependent apoptosis.
• Key POL-1 pathway genes, including RRN3 and POLR1D, were significantly down-regulated in BMS, while P53 target genes showed expression consistent with P53 activation. RRN3 silencing increased PBMC apoptosis in RRMS patients.

Conclusions:

• Suppression of the POL-1 pathway is a key molecular feature contributing to the low disease activity characteristic of benign multiple sclerosis (BMS).
• These findings highlight the role of POL-1 pathway dysregulation in the pathogenesis of BMS and suggest potential therapeutic targets.